🇺🇸 FLUAD Quadrivalent in United States

216 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 216

Most-reported reactions

1. Atrial Fibrillation — 39 reports (18.06%)
2. Hypomagnesaemia — 35 reports (16.2%)
3. Dizziness — 25 reports (11.57%)
4. Chest Pain — 23 reports (10.65%)
5. Fatigue — 20 reports (9.26%)
6. Palpitations — 18 reports (8.33%)
7. Pain — 17 reports (7.87%)
8. Covid-19 — 14 reports (6.48%)
9. Dyspnoea — 13 reports (6.02%)
10. Fall — 12 reports (5.56%)

Source database →

Frequently asked questions

Is FLUAD Quadrivalent approved in United States?

FLUAD Quadrivalent does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for FLUAD Quadrivalent in United States?

Centers for Disease Control and Prevention is the originator. The local marketing authorisation holder may differ — check the official source linked above.